Review argues cannabis safety evidence is insufficient to support legalization, highlighting harms to mood, cognition, and driving

A comprehensive review argued that acute and chronic cannabis use harms mood, psychiatric outcomes, cognition, driving ability, and general health, and that the public perception of cannabis as low-risk is unsupported by scientific evidence.

Ford, Talitha C et al.·Current drug abuse reviews·2017·Moderate EvidenceReview
RTHC-01383ReviewModerate Evidence2017RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

The review surveyed evidence across multiple domains of cannabis harm. Acute and chronic use was associated with negative effects on mood states, psychiatric outcomes (including psychosis risk), neurocognition, driving ability, and general health.

The review noted that cannabis is "highly addictive" and that withdrawal effects can drive continued use. While CBD has demonstrated antioxidant, anticonvulsant, anti-inflammatory, and neuroprotective properties, high-potency recreational cannabis is characterized by high THC and low CBD, maximizing the harmful components.

The authors concluded that "there is insufficient evidence to support the safety of cannabis and its subsequent legalisation for recreational use" and that medical cannabis use "should be done with care."

Key Numbers

Domains of harm: mood, psychiatric outcomes, neurocognition, driving, general health. High-potency cannabis: high THC, low CBD. CBD properties: antioxidant, anticonvulsant, anti-inflammatory, neuroprotective.

How They Did This

Narrative review covering acute and chronic effects of cannabis on psychological, cognitive, psychiatric, and physical health outcomes.

Why This Research Matters

As cannabis legalization advances globally, this review provides a counterpoint by comprehensively cataloging documented harms. The distinction between high-THC recreational products and CBD-rich medical preparations is important for understanding why recreational and medical cannabis may have very different risk profiles.

The Bigger Picture

The tension between cannabis's documented harms and growing social acceptance reflects a broader debate about how society weighs individual freedom against public health. This review falls firmly on the public health caution side, though critics might note that similar arguments could be made about alcohol, which remains legal.

What This Study Doesn't Tell Us

Narrative review that selectively presents evidence for harm. Does not systematically compare cannabis risks to those of legal substances like alcohol and tobacco. The claim that cannabis is "highly addictive" is debatable, as dependence rates are lower than for alcohol, tobacco, or opioids. The review does not adequately address dose-response relationships or differences between occasional and heavy use.

Questions This Raises

  • ?Would regulated cannabis markets (with potency limits, age restrictions, and quality controls) address many of the harms cited?
  • ?How do cannabis risks compare quantitatively to alcohol and tobacco?
  • ?Can CBD-rich, low-THC products provide medical benefits with minimal risk?

Trust & Context

Key Stat:
High-potency recreational cannabis: high THC + low CBD = maximum risk, minimum protection
Evidence Grade:
Narrative review covering multiple outcome domains. Provides a useful compilation of harm evidence but may present a one-sided perspective.
Study Age:
Published in 2017. The legalization debate has continued with additional evidence on both harms and potential benefits.
Original Title:
Cannabis: An Overview of its Adverse Acute and Chronic Effects and its Implications.
Published In:
Current drug abuse reviews, 10(1), 6-18 (2017)
Database ID:
RTHC-01383

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Is cannabis actually addictive?

The review describes cannabis as "highly addictive." Cannabis dependence is recognized in the DSM-5, with about 9% of users developing dependence (compared to ~15% for alcohol and ~32% for tobacco). The characterization depends on how "highly" is defined relative to other substances.

Is medical cannabis different from recreational?

The review distinguishes between CBD (which has therapeutic properties) and high-THC recreational cannabis. Medical formulations can be designed with specific THC:CBD ratios, while recreational products are typically high in THC and low in CBD, potentially maximizing risks.

Read More on RethinkTHC

Cite This Study

RTHC-01383·https://rethinkthc.com/research/RTHC-01383

APA

Ford, Talitha C; Hayley, Amie C; Downey, Luke A; Parrott, Andrew C. (2017). Cannabis: An Overview of its Adverse Acute and Chronic Effects and its Implications.. Current drug abuse reviews, 10(1), 6-18. https://doi.org/10.2174/1874473710666170712113042

MLA

Ford, Talitha C, et al. "Cannabis: An Overview of its Adverse Acute and Chronic Effects and its Implications.." Current drug abuse reviews, 2017. https://doi.org/10.2174/1874473710666170712113042

RethinkTHC

RethinkTHC Research Database. "Cannabis: An Overview of its Adverse Acute and Chronic Effec..." RTHC-01383. Retrieved from https://rethinkthc.com/research/ford-2017-cannabis-an-overview-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.